Marktanalyse - Pulmonary Arterial Hypertension - Pipeline Review, H1 2017

Global Markets Direct
03.2017
227 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Pulmonary Arterial Hypertension - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension — Pipeline Review, H1 2017, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pulmonary Arterial Hypertension — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 9, 11, 36, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Pulmonary Arterial Hypertension - Overview 9

Pulmonary Arterial Hypertension - Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 15

Products under Development by Companies 16

Products under Development by Universities/Institutes 20

Pulmonary Arterial Hypertension - Therapeutics Assessment 21

Assessment by Target 21

Assessment by Mechanism of Action 24

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development 31

Actelion Ltd 31

APT Therapeutics Inc 31

Arena Pharmaceuticals Inc 32

Ascendis Pharma A/S 32

Asklepion Pharmaceuticals LLC 33

AVEO Pharmaceuticals Inc 33

Bial - Portela & Ca SA 34

Camurus AB 34

Celsion Corp 35

Celtaxsys Inc 35

Chiesi Farmaceutici SpA 36

Eli Lilly and Company 36

F. Hoffmann-La Roche Ltd 37

Galectin Therapeutics Inc 37

HitGen LTD 38

Insmed Inc 38

INSYS Therapeutics Inc 39

INVENT Pharmaceuticals Inc 39

Johnson & Johnson 40

Kowa Company Ltd 40

Liquidia Technologies Inc 41

MannKind Corp 41

Mast Therapeutics Inc 42

Mezzion Pharma Co Ltd 42

miRagen Therapeutics Inc 43

Morphogen-IX Ltd 43

Nippon Kayaku Co Ltd 44

Nippon Shinyaku Co Ltd 44

Northern Therapeutics Inc 45

Novartis AG 45

Peloton Therapeutics Inc 46

PhaseBio Pharmaceuticals Inc 46

Pluristem Therapeutics Inc 47

Polyphor Ltd 47

Proteo Inc 48

Pulmokine Inc 48

Reata Pharmaceuticals Inc 49

Respira Therapeutics Inc 49

Reviva Pharmaceuticals Inc 50

Selten Pharma Inc 50

Serodus ASA 51

Silence Therapeutics Plc 51

SteadyMed Therapeutics Inc 52

Suda Ltd 52

Toray Industries Inc 53

United Therapeutics Corp 53

Vivus Inc 54

Pulmonary Arterial Hypertension - Drug Profiles 55

(macitentan + tadalafil) - Drug Profile 55

acebilustat - Drug Profile 56

Antibody to Inhibit TRAIL for Pulmonary Arterial Hypertension - Drug Profile 60

Antisense Oligonucleotide to Inhibit miR-145 for Pulmonary Arterial Hypertension - Drug Profile 61

APT-602 - Drug Profile 62

ascomycin - Drug Profile 63

AV-353 - Drug Profile 64

bardoxolone methyl - Drug Profile 65

beraprost sodium SR - Drug Profile 71

BIA-51058 - Drug Profile 72

BMP-10 - Drug Profile 73

BMP-9 - Drug Profile 74

Cell Therapy to Activate eNOS for Pulmonary Arterial Hypertension - Drug Profile 75

CTX-3397 - Drug Profile 76

Drugs to Inhibit Notch3 for Pulmonary Arterial Hypertension - Drug Profile 77

esuberaprost sodium MR + treprostinil - Drug Profile 78

GMA-301 - Drug Profile 79

GMCT-01 - Drug Profile 80

GRMD-02 - Drug Profile 84

INS-1009 - Drug Profile 97

INV-240 - Drug Profile 99

JNJ-26993135 - Drug Profile 100

KAR-5585 - Drug Profile 101

L-Citrulline - Drug Profile 102

macitentan - Drug Profile 104

MD-0701 - Drug Profile 110

MFC-1040 - Drug Profile 112

MFC-2040 - Drug Profile 113

NK-104 NP - Drug Profile 114

Oligonucleotide to Inhibit Endothelin-1 for Lung Cancer, Pulmonary Arterial Hypertension and Respiratory Disorders - Drug Profile 115

Oligonucleotide to Inhibit MicroRNA-145 for Pulmonary Arterial Hypertension - Drug Profile 116

PB-1046 - Drug Profile 117

PB-1120 - Drug Profile 120

PF-543 - Drug Profile 121

PK-10453 - Drug Profile 122

PK-10571 - Drug Profile 123

PLX-PAD - Drug Profile 124

POL-6014 - Drug Profile 135

PT-2977 - Drug Profile 137

QCC-374 - Drug Profile 138

R-190 - Drug Profile 139

ralinepag - Drug Profile 141

RP-5063 - Drug Profile 143

RT-234 - Drug Profile 145

selexipag - Drug Profile 146

SER-100 - Drug Profile 151

sildenafil citrate - Drug Profile 154

sirolimus - Drug Profile 155

sirolimus albumin-bound - Drug Profile 156

Small Molecule to Inhibit ROCK-2 for Cardiovascular, Ophthalmology and Oncology - Drug Profile 158

Small Molecules for Pulmonary Arterial Hypertension - Drug Profile 159

Small Molecules to Activate ACE2 for Pulmonary Arterial Hypertension - Drug Profile 160

Small Molecules to Antagonize 5-HT1B for Pulmonary Arterial Hypertension - Drug Profile 161

Small Molecules to Antagonize PDGFR for Pulmonary Arterial Hypertension - Drug Profile 162

Small Molecules to Inhibit Soluble Epoxide Hydrolase for Pulmonary Arterial Hypertension - Drug Profile 163

sodium nitrite - Drug Profile 164

SPI-054 - Drug Profile 168

SPI-183 - Drug Profile 169

SUD-004 - Drug Profile 170

Synthetic Peptide to Antagonize Urotensin-II Receptor for Pulmonary Arterial Hypertension - Drug Profile 171

tacrolimus - Drug Profile 172

tadalafil - Drug Profile 173

tiprelestat - Drug Profile 175

tocilizumab - Drug Profile 179

TPN-729 - Drug Profile 189

TR-422 - Drug Profile 190

treprostinil diolamine - Drug Profile 191

treprostinil diolamine - Drug Profile 193

treprostinil diolamine - Drug Profile 195

treprostinil diolamine - Drug Profile 196

treprostinil diolamine SR - Drug Profile 197

ubenimex - Drug Profile 198

udenafil - Drug Profile 200

VPD-380 - Drug Profile 204

Pulmonary Arterial Hypertension - Dormant Projects 205

Pulmonary Arterial Hypertension - Discontinued Products 207

Pulmonary Arterial Hypertension - Product Development Milestones 208

Featured News & Press Releases 208

Appendix 220

Methodology 220

Coverage 220

Secondary Research 220

Primary Research 220

Expert Panel Validation 220

Contact Us 220

Disclaimer 221





List of Tables

Number of Products under Development for Pulmonary Arterial Hypertension, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Actelion Ltd, H1 2017

Pulmonary Arterial Hypertension - Pipeline by APT Therapeutics Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Arena Pharmaceuticals Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Ascendis Pharma A/S, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Asklepion Pharmaceuticals LLC, H1 2017

Pulmonary Arterial Hypertension - Pipeline by AVEO Pharmaceuticals Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Bial - Portela & Ca SA, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Camurus AB, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Celsion Corp, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Celtaxsys Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Chiesi Farmaceutici SpA, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Eli Lilly and Company, H1 2017

Pulmonary Arterial Hypertension - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Galectin Therapeutics Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by HitGen LTD, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Insmed Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by INSYS Therapeutics Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by INVENT Pharmaceuticals Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Johnson & Johnson, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Kowa Company Ltd, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Liquidia Technologies Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by MannKind Corp, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Mast Therapeutics Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Mezzion Pharma Co Ltd, H1 2017

Pulmonary Arterial Hypertension - Pipeline by miRagen Therapeutics Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Morphogen-IX Ltd, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Nippon Kayaku Co Ltd, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Nippon Shinyaku Co Ltd, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Northern Therapeutics Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Novartis AG, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Peloton Therapeutics Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by PhaseBio Pharmaceuticals Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Pluristem Therapeutics Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Polyphor Ltd, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Proteo Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Pulmokine Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Reata Pharmaceuticals Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Respira Therapeutics Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Reviva Pharmaceuticals Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Selten Pharma Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Serodus ASA, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Silence Therapeutics Plc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by SteadyMed Therapeutics Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Suda Ltd, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Toray Industries Inc, H1 2017

Pulmonary Arterial Hypertension - Pipeline by United Therapeutics Corp, H1 2017

Pulmonary Arterial Hypertension - Pipeline by Vivus Inc, H1 2017

Pulmonary Arterial Hypertension - Dormant Projects, H1 2017

Pulmonary Arterial Hypertension - Dormant Projects, H1 2017 (Contd..1), H1 2017

Pulmonary Arterial Hypertension - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Pulmonary Arterial Hypertension, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus